Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02029443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02029443 · ClinicalTrials.gov record · last posted 2026-05-05

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Name: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia — clinical trial record (NCT02029443)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorAcerta Pharma BV

Started2014-01-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Amendment record 34 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 34 times since 2014-01-06; most recent amendment 2026-05-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2016-06-22

Status change Recruiting→Active, Not Recruitingv12

2014-01-17

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT02029443
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Enrollment	306 participants
Start Date	2014-01-30
Primary Completion	2021-07-15 (estimated)
Study Completion	2027-06-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-05